[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"non-alcoholic-steatohepatitis-nash\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:non-alcoholic-steatohepatitis-nash":62},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,48],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100606837","phase-4-empagliflozin-versus-statins-in-non-alcoholic-fatty-liver-disease-100606837",false,"NCT07180745","Empagliflozin Versus Statins in Non-Alcoholic Fatty Liver Disease","Assessment of Efficacy of Empagliflozin Versus Statins in Treatment of Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis","Inclusion Criteria:\n\n* Adult\n* Obese\n* Hyperlipidemic\n* Diabetic patients\n* Diagnosed with non-alcoholic fatty liver disease and non-alcoholic Steatohepatitis\n\nExclusion Criteria:\n\n* Pregnant women\n* Breast feeding women\n* Diabetic patients with ketoacidosis\n* Hyperlipidemic patients with cardiovascular dysfunction\n* Patients with NAFLD or NASH induced hepatocellular carcinoma\n* Hyperlipidemic obese diabetic patients diagnosed with NAFLD or NASH who will refuse to sign the informed consent","ALL","18 Years","65 Years",{"count":20,"type":21},400,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","The goal of this clinical trial is to assess the efficacy of Empagliflozin versus Statins as monotherapy and polytherapy in non-alcoholic fatty liver disease and non-alcoholic Steatohepatitis.\n\nDoes drug ABC Empagliflozin versus Statins as monotherapy and polytherapy improve the controlled attenuation parameter (CAP), the liver stiffness measurement (LSM), the proportion of patients with at least one point improvement or one-stage reduction in the histological scores with respect to hepatic steatosis, hepatocellular ballooning, lobular inflammation, and fibrosis after treatment?\n\nWhat medical problems do participants have when taking Empagliflozin versus Statins as monotherapy and polytherapy?\n\nParticipants will:\n\n* Take Empagliflozin alone or Empagliflozin plus statins or Pioglitazone plus Statins or Pioglitazone alone as standard therapy every day for 3 months\n* Be directed to complete history taking. FibroScan®, abdominal ultrasound and laboratory tests of ALT, AST, ALP, platelets count, Triglycerides, Cholesterol, LDL, HDL, serum insulin and insulin resistance will be conducted at baseline and after the drug administration for 3 months.\n* Keep a diary of recording any side effects they use a rescue inhaler",[27,28],"Non-alcoholic Fatty Liver Disease NAFLD","Non-alcoholic Steatohepatitis NASH",[30,31,32,33,34],"Empagliflozin","Statin","Pioglitazone","NAFLD","NASH","NOT_YET_RECRUITING","2025-09-16",{"date":38,"type":39},"2025-09-18","ACTUAL",{"date":41,"type":21},"2025-11-01",{"date":43,"type":21},"2026-03-01",{"name":45,"class":46},"Badr University","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":55,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":47},"100297397","longitudinal-observational-study-of-chinese-with-nafldnash-100297397","NCT03151473","Longitudinal Observational Study Of Chinese With NAFLD\u002FNASH","Prospective Cohort Assessing The Prevalence And Progress Of Non-Alcoholic Fatty Liver Disease (NAFLD)\u002FNon-Alcoholic Steatohepatitis (NASH) In Chinese Subjects","Inclusion Criteria:\n\n* Males or females aged 18 and older;\n* Adults being managed or treated for NAFL or NASH;\n* Be able to communicate meaningfully with the Investigator and be legally competent to provide written informed consent.\n\nExclusion Criteria:\n\n* Incompetent to understand and\u002For sign the informed consent;\n* Ethanol consumption exceeding more than 14 standard beverages per week for males and more than 7 standard beverages per week for female;\n* Causes for secondary hepatic fat accumulation such as significant alcohol consumption, medications, Wilson's disease, viral infections, starvation or parenteral nutrition, among others, and conditions associated with microvesicular steatosis\n* Diagnosis of liver cirrhosis and\u002For hepatocellular carcinoma;\n* Diagnosis of chronic inflammatory disease (i.e. inflammatory bowel disease, rheumatoid arthritis, inflammatory lung disease, severe infectious diseases), other than NAFL\u002FNASH.",true,{"count":57,"type":21},20000,"OBSERVATIONAL","This is a 10-year, longitudinal, observational study of patients with NAFLD\u002FNASH designed to specifically address important clinical questions that remain incompletely answered from registration trials. In addition to the study database, the biospecimen repository will also be included so that translational studies of genomics and biomarkers of response may be performed.",[61,62],"Non-Alcoholic Fatty Liver Disease (NAFLD)","Non-Alcoholic Steatohepatitis (NASH)","RECRUITING","2025-03-21",{"date":66,"type":39},"2025-03-24",{"date":68,"type":39},"2017-05-08",{"date":70,"type":21},"2027-09-30",{"name":72,"class":46},"Humanity and Health Research Centre"]